Quoin Pharmaceuticals, Ltd. American Depositary Shares
QNRX US74907L2016
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -80% | -95% | -72% | -87% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Culverwell Anthony James O |
0.45 USD |
100,000 Bought |
45,000 USD |
23/12/2024 | 23/12/2024 |
| Myers Michael CEO |
0.45 USD |
555,556 Bought |
250,000 USD |
23/12/2024 | 23/12/2024 |
| Dunn Gordon CFO |
0.45 USD |
122,221 Bought |
54,999 USD |
23/12/2024 | 23/12/2024 |
| Carter Denise P. COO |
0.45 USD |
555,556 Bought |
250,000 USD |
23/12/2024 | 23/12/2024 |
| Dunn Gordon CFO |
0.71 USD |
10,000 Bought |
7,100 USD |
09/09/2024 | 10/09/2024 |
| Dunn Gordon CFO |
0.91 USD |
10,000 Bought |
9,100 USD |
09/09/2024 | 10/09/2024 |
| Dunn Gordon CFO |
0.80 USD |
4,000 Bought |
3,200 USD |
09/09/2024 | 09/09/2024 |
| Dunn Gordon CFO |
0.78 USD |
4,000 Bought |
3,120 USD |
09/09/2024 | 09/09/2024 |
| Dunn Gordon CFO |
0.80 USD |
856 Bought |
685 USD |
09/09/2024 | 09/09/2024 |
| Carter Denise P. COO |
0.75 USD |
8,825 Bought |
6,602 USD |
03/09/2024 | 04/09/2024 |